[go: up one dir, main page]

MXPA06014082A - Sistema y metodo para el suministro transdermico de un anticoagulante. - Google Patents

Sistema y metodo para el suministro transdermico de un anticoagulante.

Info

Publication number
MXPA06014082A
MXPA06014082A MXPA06014082A MXPA06014082A MXPA06014082A MX PA06014082 A MXPA06014082 A MX PA06014082A MX PA06014082 A MXPA06014082 A MX PA06014082A MX PA06014082 A MXPA06014082 A MX PA06014082A MX PA06014082 A MXPA06014082 A MX PA06014082A
Authority
MX
Mexico
Prior art keywords
anticoagulant
derivative
benzamidine
maintain
transdermal delivery
Prior art date
Application number
MXPA06014082A
Other languages
English (en)
Inventor
Joseph B Phipps
Sudeep Takhar
Rama V Padmanabhan
Janardhanan A Subramony
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of MXPA06014082A publication Critical patent/MXPA06014082A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0432—Anode and cathode
    • A61N1/044—Shape of the electrode
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0448—Drug reservoir

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medical Informatics (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Electrotherapy Devices (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un dispositivo para suministrar transdermicamente un agente anticoagulante por electrotransporte; preferiblemente el anticoagulante comprende un derivado de benzamidina o naftamidina; un derivado de benzamidina particularmente preferido es la 2-[3-[4-(4-piperidiniloxi)anilino]-1-propenil]benzamidina; los dispositivos estan configurados para mantener una concentracion plasmatica de 20-80 ng/mL o proveer un flujo en la escala de aproximadamente 20-40 mg/dia; las densidades de corriente adecuadas incluyen 0.050 mA/cm2 y 0.10 mA/cm2; los metodos de la invencion incluyen suministrar los anticoagulantes para mantener con precision las concentraciones plasmaticas deseadas, la invencion tambien comprende tratar la enfermedad tromboembolica e inhibir el factor Xa.
MXPA06014082A 2004-06-03 2005-06-01 Sistema y metodo para el suministro transdermico de un anticoagulante. MXPA06014082A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57690504P 2004-06-03 2004-06-03
PCT/US2005/019576 WO2005120482A1 (en) 2004-06-03 2005-06-01 System and method for transdermal delivery of an anticoagulant

Publications (1)

Publication Number Publication Date
MXPA06014082A true MXPA06014082A (es) 2007-05-09

Family

ID=35033286

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06014082A MXPA06014082A (es) 2004-06-03 2005-06-01 Sistema y metodo para el suministro transdermico de un anticoagulante.

Country Status (18)

Country Link
US (1) US20050273047A1 (es)
EP (1) EP1758568A1 (es)
JP (1) JP2008501434A (es)
KR (1) KR20070027582A (es)
CN (1) CN1972681A (es)
AR (1) AR049434A1 (es)
AU (1) AU2005251772A1 (es)
BR (1) BRPI0511740A (es)
CA (1) CA2568625A1 (es)
IL (1) IL179675A0 (es)
MX (1) MXPA06014082A (es)
NO (1) NO20065985L (es)
NZ (1) NZ551359A (es)
PE (1) PE20060099A1 (es)
RU (1) RU2006147274A (es)
UY (1) UY28935A1 (es)
WO (1) WO2005120482A1 (es)
ZA (1) ZA200700051B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007120747A2 (en) * 2006-04-13 2007-10-25 Nupathe Inc. Transdermal methods and systems for the delivery of anti-migraine compounds
US20070249988A1 (en) * 2006-04-21 2007-10-25 Alza Corporation Electrotransport Delivery of Nesiritide
EP2310091B1 (en) * 2008-05-09 2014-07-16 Wetling Holding ApS Ionized gas for medical treatment
US8428708B1 (en) * 2012-05-21 2013-04-23 Incline Therapeutics, Inc. Self-test for analgesic product
US8428709B1 (en) 2012-06-11 2013-04-23 Incline Therapeutics, Inc. Current control for electrotransport drug delivery
EP3342452A1 (en) * 2017-01-03 2018-07-04 L'oreal Systems including association of ellagic acid and microcurrent
IL285942B2 (en) * 2019-03-18 2025-08-01 Rambam Medtech Ltd Alternating charge to inhibit sorption to surfaces exposed to biological materials
US20240299372A1 (en) * 2023-03-07 2024-09-12 Pike Therapeutics Inc. Transdermal Drug Delivery Systems for Administration of a Therapeutically Effective Amount of Apixaban and Other Direct Oral Anticoagulants

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141359A (en) * 1976-08-16 1979-02-27 University Of Utah Epidermal iontophoresis device
US4340047A (en) * 1978-10-18 1982-07-20 Robert Tapper Iontophoretic treatment apparatus
US4250878A (en) * 1978-11-22 1981-02-17 Motion Control, Inc. Non-invasive chemical species delivery apparatus and method
US4382529A (en) * 1980-12-15 1983-05-10 Drdlik Frank J Sanitary dispensing closure
US4406658A (en) * 1981-03-06 1983-09-27 Medtronic, Inc. Iontophoretic device with reversible polarity
US4456012A (en) * 1982-02-22 1984-06-26 Medtronic, Inc. Iontophoretic and electrical tissue stimulation device
US4722726A (en) * 1986-02-12 1988-02-02 Key Pharmaceuticals, Inc. Method and apparatus for iontophoretic drug delivery
US5496266A (en) * 1990-04-30 1996-03-05 Alza Corporation Device and method of iontophoretic drug delivery
US5047007A (en) * 1989-12-22 1991-09-10 Medtronic, Inc. Method and apparatus for pulsed iontophoretic drug delivery
US5637599A (en) * 1994-06-17 1997-06-10 Corvas International, Inc. Arginine mimic derivatives as enzyme inhibitors
US5983130A (en) * 1995-06-07 1999-11-09 Alza Corporation Electrotransport agent delivery method and apparatus
EP0950407B1 (en) * 1998-04-14 2002-09-04 Hisamitsu Pharmaceutical Co., Inc. The use of a GP IIb/IIIa antagonist for the manufacture of a medicament suitable for transdermal application by iontophoresis
JP2001055332A (ja) * 1999-06-07 2001-02-27 Saitama Daiichi Seiyaku Kk 芳香族アミジン誘導体類含有のイオントフォレ−シス用製剤
US6496728B2 (en) * 2000-02-18 2002-12-17 University Of Utah Research Foundation Methods for extracting substances using alternating current
US7137975B2 (en) * 2001-02-13 2006-11-21 Aciont, Inc. Method for increasing the battery life of an alternating current iontophoresis device using a barrier-modifying agent
US6775570B2 (en) * 2002-02-04 2004-08-10 Ceramatec, Inc. Iontophoretic treatment device
WO2005051485A1 (en) 2003-11-19 2005-06-09 Alza Corporation Peptidically buffered formulations for electrotransport applications and methods of making

Also Published As

Publication number Publication date
BRPI0511740A (pt) 2008-01-08
NO20065985L (no) 2007-02-28
US20050273047A1 (en) 2005-12-08
AR049434A1 (es) 2006-08-02
IL179675A0 (en) 2008-03-20
CA2568625A1 (en) 2005-12-22
EP1758568A1 (en) 2007-03-07
WO2005120482A1 (en) 2005-12-22
UY28935A1 (es) 2005-07-29
JP2008501434A (ja) 2008-01-24
RU2006147274A (ru) 2008-07-20
AU2005251772A1 (en) 2005-12-22
NZ551359A (en) 2009-03-31
PE20060099A1 (es) 2006-02-18
KR20070027582A (ko) 2007-03-09
ZA200700051B (en) 2008-04-30
CN1972681A (zh) 2007-05-30

Similar Documents

Publication Publication Date Title
WO2005012485A3 (en) Methods for treating diabetes and related disorders using pde10a inhibitors
WO2005107726A3 (en) Method for the treatment of back pain
WO2005042700A3 (en) Use of hedgehog pathway inhibitors in small-cell lung cancer
MXPA06014082A (es) Sistema y metodo para el suministro transdermico de un anticoagulante.
TW200607505A (en) Fused heterocyclic kinase inhibitors
ATE537873T1 (de) Verfahren und gerät zur kontrolle der extrasystolischen stimulationstherapie (ess) mit ischämie-nachweis
FI7341U1 (fi) Transdermaalinen laastari fentanyylin antamiseksi
BR0115511A (pt) Métodos para tratar hipercolesterolemia familiar heterozigótica, e para reduzir ldl-c, elevar hdl-c, reduzir apo b e elevar apo a-1 em um paciente que sofre de hipercolesterolemia familiar heterozigótica, e, uso de ácido (e) -7- [4- (4- fluorefenil) -6- isopropil-2- [metil (metilsulfonil) amino] pirimidin -5- il] (3r,5s) - 3,5- di - hidroxihept -6- enóico ou de um sal farmaceuticamente aceitável do mesmo
Patel et al. In vitro and in vivo evaluation of the transdermal iontophoretic delivery of sumatriptan succinate
WO2007041300A3 (en) Iontophoresis method and apparatus for systemic delivery of active agents
Schiffrin et al. Effect of chronic ETA‐selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats
ATE380807T1 (de) N-oxid von n-phenyl-2-pyrimidinaminderivaten
CY1106256T1 (el) Ιοντοφορητικη χορηγηση ροτιγκοτινης για τη θepαπεια της νοσου του parkinson
ATE367805T1 (de) Transdermale vorrichtung
ATE424211T1 (de) Therapeutische verwendung von sapogeninen
ATE359079T1 (de) Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
ATE406364T1 (de) Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
ATE423561T1 (de) Verwendung von glucosidase-hemmern zur behandlung von mukoviszidose
TW200507840A (en) Method of treating multiple myeloma
EA200501166A1 (ru) Составы и способы лечения тромбоцитемии
WO2007076310A3 (en) Iontophoretic transdermal delivery of nicotine salts
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
MXPA04008195A (es) Metodos para el tratamiento de la diabetes empleando inhibidores de pde11a.
ATE363905T1 (de) 2-phenyl-benzimidazol und 2-phenyl-imidazo-4,5)- pyridin-derivate als checkpoint-kinase-cds1 (chk2)-hemmer zur behandlung von krebs
CY1105117T1 (el) Θepαπειες για τη χρονια νεφρικη ανεπαρκεια χρησιμοποιωντας ανταγωνιστες των ενσωματινων